BioSpace News Archive

Takeda has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka.

HUTCHMED Limited will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylight Time / 12:00 noon British Summer Time / 7:00 pm Hong Kong Time.

Antengene Corporation Limited announced that South Korea’s National Health Insurance Service has approved the reimbursement of XPOVIO® for the treatment of adult patients with relapsed or refractory multiple myeloma.

ANEW MEDICAL, INC. announces that is has been granted and issued a patent in Europe, EP3377091B1, for the use of ANEW’s secreted Klotho gene sequence and gene delivery systems to be used in the treatment of diminished cognition, memory loss, dementia and other neurodegenerative diseases.

ENCell Co., Ltd. , a biotech in South Korea specializing in Cell and Gene therapy (CGT), presented promising results from their First-in-Human Phase 1 clinical trial of the novel mesenchymal stem cell therapy (EN001) for Charcot-Marie-Tooth disease type 1A (CMT1A) at the Peripheral Nerve Society (PNS) annual meeting in Montreal on June 23, 2024.

Star Therapeutics today announced the presentation of clinical data from VIVID 1 (VGA039 Investigation in Von Willebrand Disease), a Phase 1 clinical study of VGA039 in healthy volunteers.

Intellia Therapeutics, Inc. today announced the appointment of Edward Dulac as Executive Vice President, Chief Financial Officer (CFO), and Treasurer, effective July 22, 2024.

Bluejay Diagnostics, Inc., announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 in patients diagnosed with sepsis and septic shock.

Surgence™, a cloud-based digital platform created by Concordance Innovations, a wholly owned subsidiary of Concordance Healthcare Solutions, is pleased to announce a collaboration with Mayo Clinic to integrate Surgence into their digital supply chain, enhancing the Surgence platform.

Concerto Biosciences, a Cambridge-based biotechnology company, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 1, first-in-human trial of Ensemble No.2 (ENS-002), an investigational live biotherapeutic product (LBP) to treat atopic dermatitis (AD).